The weekly litigation news digest is live. Subscribe now

IP Verse

Methods For Reducing Lipoprotein(A) Levels By Administering An Inhibitor Of Proprotein Convertase Subtilisin Kexin-9 (Pcsk9) - EP2756004

The patent EP2756004 was granted to Regeneron Pharmaceuticals on Dec 25, 2019. The application was filed on Sep 12, 2012 under application number EP12761864A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP2756004

REGENERON PHARMACEUTICALS
Application Number
EP12761864A
Filing Date
Sep 12, 2012
Status
Opposition Rejected
Apr 19, 2024
Publication Date
Dec 25, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
BOEHMERT & BOEHMERT ANWALTSPARTNERSCHAFT MBBSep 25, 2020ENGELHARDADMISSIBLE
AMGENDec 27, 2019DORRIESADMISSIBLE
AMGENDec 27, 2019DORRIES, HANS ULRICH , DF-MP DORRIES FRANK-MOLNIA & POHLMANADMISSIBLE

Patent Citations (7) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS2010166768
DESCRIPTIONUS6596541
EXAMINATIONUS2010166768
INTERNATIONAL-SEARCH-REPORTWO2011028938
OPPOSITIONUS2010166768
OPPOSITIONWO2015054619
OTHERUS2010166768

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents